Tikun Olam-Cannbit Pharmaceuticals Ltd
Tel Aviv Stock Exchange TKUN.TA
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure for the year ending December 31, 2023: USD -301.57 K
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure is USD -301.57 K for the year ending December 31, 2023, a 91.09% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure for the year ending December 31, 2022 was USD -3.38 M, a -1.96% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure for the year ending December 31, 2021 was USD -3.32 M, a 59.45% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure for the year ending December 31, 2020 was USD -8.18 M, a -118.68% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Capital Expenditure for the year ending December 31, 2019 was USD -3.74 M, a -711.30% change year over year.
Key data
| Date | Capital Expenditure | Free Cash Flow | Depreciation And Amortization | Deferred Income Tax |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: TKUN.TA
| CEO | Mr. Ronen Elad |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | Hitad 2 |
| Employees | 50 |
| Sector | Health Care |
| Industries | |
Description
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. It also provides training and patient care services. The company is based in Nof Hagalil, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email